Lymphoma  >>  Gazyva (obinutuzumab) 
Welcome,         Profile    Billing    Logout  

107 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
BP43131, NCT05219513: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
200
Europe, US, RoW
RO7443904, Glofitamab, RO7082859, Obinutuzumab, Tocilizumab, Actemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
04/25
04/25
NCT05653271: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Recruiting
1
42
US, RoW
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Acepodia Biotech, Inc.
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma
09/25
09/27
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
1
25
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Chronic Lymphocytic Leukemia
01/26
01/27
CO43805, NCT05169515: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
1
121
Europe, US, RoW
SC Mosunetuzumab, RO7030816, IV Glofitamab, RO7082859, CC-220, CC-99282, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
Non-Hodgkin Lymphoma
07/26
07/28
URBAN, NCT04034056: Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study

Completed
N/A
299
Europe
Obinutuzumab
Hoffmann-La Roche
Follicular Lymphoma
04/24
04/24
NCT05950997: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Recruiting
N/A
89
RoW
Acalabrutinib, Obinutuzumab
The First Affiliated Hospital with Nanjing Medical University, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
09/26
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
N/A
400
Europe
Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro®
iOMEDICO AG, BeiGene Switzerland GmbH
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
04/27
04/27
 

Download Options